Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: VLAD who wrote (16858)	12/11/1998 1:58:00 PM
From: VLAD	Read Replies (1) \| Respond to of 23519

Actually ONE down FOUR to go: 5)Wilson's resignation Also throw in other tidbits that should help, including more international approvals, Alibra phase III trial completion in mid 1999, Dr Christ to present gene therapy research next month, ACC findings on Viagra safety in January journal, Viagra to be black boxed, Pfizer to have class action lawsuits filed for endangering the public health. IMO, Vivus would be wise to negotiate with a well known biotech company to join them in the development and sales of the potential gene therapy drug. An association with the likes of Amgen or what ever large biotech is at the forefront of efficient techniques of DNA based drugs would be wise. Gene therapy would make Viagra obsolete in organic vascular cases.